To this end, the clinical surveillance accompanied by early assessment and persistent monitoring of cardiac‐specific biomarkers including cTnI/T, NT‐proBNP, Mb and CK‐MB, as well as coagulation indicators such as d‐dimer, thrombocyte count, PT and Hyc, may identify timely cardiac injury and predict COVID‐19 complications after hospitalization. Here, MB is linked to COVID-19.